BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15492253)

  • 1. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma.
    Hann HW; Lee J; Bussard A; Liu C; Jin YR; Guha K; Clayton MM; Ardlie K; Pellini MJ; Feitelson MA
    Cancer Res; 2004 Oct; 64(20):7329-35. PubMed ID: 15492253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings].
    Tong GD; Zhou DQ; He JS; Xiao CL; Liu XL; Zhou XZ; Zhang X; Xing YF; Lü P; Feitelson MA
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):828-32. PubMed ID: 18073065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
    Momosaki S; Nakashima Y; Kojiro M; Tabor E
    J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.
    Wang W; Zhao LJ; Wang Y; Tao QY; Feitelson MA; Zhao P; Ren H; Qi ZT
    Cancer Biomark; 2011-2012; 11(1):29-39. PubMed ID: 22820138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients.
    Toyoda H; Kumada T; Kaneoka Y; Murakami Y
    J Hepatol; 2008 Jan; 48(1):43-50. PubMed ID: 18023912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma.
    Yeh CT; Shen CH; Tai DI; Chu CM; Liaw YF
    Oncogene; 2000 Nov; 19(46):5213-20. PubMed ID: 11077437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis.
    Elefsiniotis IS; Diamantis ID; Dourakis SP; Kafiri G; Pantazis K; Mavrogiannis C
    Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):721-6. PubMed ID: 12811301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma.
    Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS
    Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
    Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
    Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of HBsAg-negative but anti-HBc-positive hepatocellular carcinoma in a hepatitis B virus endemic area.
    Shim J; Kim BH; Kim NH; Dong SH; Kim HJ; Chang YW; Lee JI; Chang R
    J Gastroenterol Hepatol; 2005 May; 20(5):746-51. PubMed ID: 15853989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of patients with HCC who are negative for both HBV and HCV markers.
    Watabe H; Shiratori Y; Tateishi R; Fujishima T; Akamatsu M; Koike Y; Obi S; Hamamura K; Sato S; Teratani T; Shiina S; Omata M
    Hepatogastroenterology; 2003; 50(54):2157-60. PubMed ID: 14696486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profile of nine novel genes differentially expressed in hepatitis B virus-associated hepatocellular carcinomas.
    Kim MY; Park E; Park JH; Park DH; Moon WS; Cho BH; Shin HS; Kim DG
    Oncogene; 2001 Jul; 20(33):4568-75. PubMed ID: 11494152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.
    Ming L; Thorgeirsson SS; Gail MH; Lu P; Harris CC; Wang N; Shao Y; Wu Z; Liu G; Wang X; Sun Z
    Hepatology; 2002 Nov; 36(5):1214-20. PubMed ID: 12395332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags.
    Yoon SY; Kim JM; Oh JH; Jeon YJ; Lee DS; Kim JH; Choi JY; Ahn BM; Kim S; Yoo HS; Kim YS; Kim NS
    Int J Oncol; 2006 Aug; 29(2):315-27. PubMed ID: 16820872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
    Elkady A; Tanaka Y; Kurbanov F; Oynsuren T; Mizokami M
    J Gastroenterol Hepatol; 2008 Mar; 23(3):474-81. PubMed ID: 18318825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma.
    Tanaka H; Iwasaki Y; Nouso K; Kobayashi Y; Nakamura S; Matsumoto E; Toshikuni N; Kaneyoshi T; Ohsawa T; Takaguchi K; Fujio K; Senoh T; Ohnishi T; Sakaguchi K; Shiratori Y
    J Gastroenterol Hepatol; 2005 Jun; 20(6):850-6. PubMed ID: 15946131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.
    Xu J; Shi J; Wang YP; Lin Y; Chen YX; Lu J; Zeng X; Xie WF
    Med Sci Monit; 2009 Jun; 15(6):CR274-9. PubMed ID: 19478697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.